Physician profile
Robin Rinearson
NPI 1649207150
$735.12
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $298 · 2020: $246 · 2021: $169 · 2022: $21.87.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $236.56 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $88.77 | 2019-2020 | |
| Alcon Vision LLC | $72.81 | 2019-2021 | |
| Maculogix, INC. | $57.61 | 2019-2020 | |
| Optos, INC. | $43.30 | 2019 | |
| Kala Pharmaceuticals, INC. | $42.83 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $38.35 | 2020-2021 | |
| Carl Zeiss Meditec USA, INC. | $34.44 | 2021 | |
| Coopervision INC. | $27.69 | 2019-2020 | |
| Dompe US, INC. | $23.19 | 2021 | |
| Shire North American Group INC | $19.46 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Novartis Pharmaceuticals Corporation | $13.47 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Rinearson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.